Afzal |
2019 |
USA |
Ipil/Pemb |
Melanoma |
UK |
single-center |
at the
time of ICIs initiation |
OS |
120 |
29 (24.2%) |
5 |
Zhao |
2019 |
China |
Pemb/Nivo/SHR-1210 |
NSCLC |
1,2,3ormore |
single-center |
within 1 month before or after ICIs initiation |
PFS and
OS |
109 |
40(36.7%) |
7 |
Chalabi |
2020 |
worldwide |
Atezo |
NSCLC |
2or more |
multicenter |
30
days before and after ICIs initiation |
PFS and OS |
757 |
234(31%) |
8 |
Cortellini |
2020 |
Italy |
Pemb/Nivo/Atezo |
NSCLC /Melanoma/RCC and
others |
1or more |
multicenter |
within the 30 days before ICIs
initiation |
ORR, PFS and OS. |
1012 |
491 (48.5%) |
7 |
Hopkins |
2020 |
Worldwide |
Atezo |
advanced urothelial cancer |
1or 2 |
multicenter |
30 days prior and after ICIs initiation. |
PFS and OS |
1360 |
471 (35%) |
8 |
Santamaría |
2020 |
Spain |
Pemb/Nivo/Atezo/Ipil |
NSCLC/RCC/Melanoma/bladder cancer |
1or 2 or more |
multicenter |
within
4 weeks before or after ICIs started or any time later |
PFS and OS |
102 |
78 (77.2%) |
7 |
Svaton |
2020 |
Czech |
Nivo |
NSCLC |
1or 2 or more |
multicenter |
1
month before and after ICIs initiation |
PFS and OS |
224 |
64 (28.6%) |
6 |
Buti |
2020 |
Italy |
Pemb/Nivo |
NSCLC, melanoma, renal cell carcinoma,
others |
any |
single-center |
within 30 days before ICIs initiation |
ORR, PFS and OS. |
217 |
104 (47.9%) |
6 |
Cortellini |
2021 |
Italy and UK |
Pemb |
NSCLC |
first- line |
multicenter |
within the 30 days before ICIs initiation |
ORR, PFS and
OS. |
950 |
474 (49.9%) |
7 |
Gaucher |
2021 |
France |
Ipil/Pemb/Nivo |
Melanoma |
1,2,3ormore |
single-center |
upon initiation of ICI treatment or in the following 60
days |
OS |
108 |
39 (36.2%) |
6 |
Husain |
2021 |
USA |
PD1/L1/CTLA-4 |
NSCLC and Melanoma |
1or 2 |
single-center |
at time of ICIs |
OS |
1091 |
415 (38%) |
7 |
Jun |
2021 |
USA, Europe, and Asia |
PD-1/CTLA-4 |
HCC |
1,2,3ormore |
multicenter |
within 30 days before ICI initiation |
ORR and OS |
314 |
110(35%) |
7 |
Peng |
2021 |
USA |
Nivo/Pemb |
NSCLC, Melanoma, RCC, TCC, or HNSCC |
1,2,3ormore |
single-center |
0 to 30 days before or after ICIs
initiation |
PFS and OS |
233 |
89 (38.2%) |
7 |
Bañobre |
2021 |
Spain |
Atezo/Pemb/Nivo |
metastatic urothelial
carcinoma |
1or 2 or more |
multicenter |
30 days before the start of
first ICIs infusion. |
ORR, DCR, PFS and OS |
119 |
54 (45%) |
6 |